Injection Pens - Global Strategic Business Report

Global Injection Pens Market to Reach $71.9 Billion by 2030

The global market for Injection Pens estimated at US$45.1 Billion in the year 2022, is projected to reach a revised size of US$71.9 Billion by 2030, growing at a CAGR of 6% over the analysis period 2022-2030. Disposable, one of the segments analyzed in the report, is projected to record 5.6% CAGR and reach US$50 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Reusable segment is readjusted to a revised 6.9% CAGR for the next 8-year period.

The U.S. Market is Estimated at $12.1 Billion, While China is Forecast to Grow at 8.9% CAGR

The Injection Pens market in the U.S. is estimated at US$12.1 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$16.3 Billion by the year 2030 trailing a CAGR of 8.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.1% and 5.5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Select Competitors (Total 19 Featured) -

• AstraZeneca PLC
• Becton, Dickinson & Company
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Haselmeier GmbH
• Merck & Co., Inc.
• Novartis International AG
• Novo Nordisk A/S
• Owen Mumford Ltd.
• Pfizer, Inc.
• Sanofi S.A.
• Ypsomed AG

What's New?

• Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and Research Platform
• Complimentary updates for one year